The Society for Maternal-Fetal Medicine supports the clinical practice of maternal-fetal medicine by providing education, promoting research, and engaging in advocacy to optimize the health of high-risk pregnant women and their babies.
This Consult has been endorsed by the American College of Obstetricians and Gynecologists (ACOG) and replaces the Society for Maternal-Fetal Medicine's (SMFM) Statement #4, Implementation of the use of antenatal corticosteroids in the late preterm birth period in women at risk for preterm delivery, August 2016.
Read More
The COVID-19 global pandemic has broad implications for obstetrical care and perinatal outcomes. As we approach the 2-year mark into an unprecedented international pandemic, this review presents the progress and opportunities for research related to COVID-19 and pregnancy.
Read More
Register for SMFM's 42nd Annual Pregnancy Meeting
September 13th 2021Registration is now open for the Society for Maternal-Fetal Medicine's (SMFM) 42nd Annual Pregnancy Meeting, to be held from January 31 to February 5, 2022, at the Gaylord Palms Resort and Convention Center near Orlando, Florida.
Read More
Navigating the Annual Pregnancy Meeting
January 4th 2021The Society for Maternal-Fetal Medicine’s (SMFM) 2021 Annual Pregnancy Meeting will be held virtually throughout the month of January, with core meeting activities taking place Jan. 25-30. SMFM’s President, Judette Louis, MD, MPH, and Program Committee Chair, Cynthia Gyamfi-Bannerman, MD, MSc, tell readers what they can expect in the new online format.
Read More
Cesarean scar pregnancy (CSP) is a complication in which an early pregnancy implants in the scar from a prior cesarean delivery. Incidence and recognition of this condition appear to have increased over the past two decades, perhaps due to high worldwide cesarean delivery rates. The clinical presentation is variable, and many women are asymptomatic at presentation. CSP can be difficult to diagnose in a timely fashion. Ultrasound is the primary imaging modality for CSP diagnosis. Expectantly managed CSP is associated with high rates of severe maternal morbidity such as hemorrhage, placenta accreta spectrum (PAS), and uterine rupture. Given these substantial risks, pregnancy termination is recommended after CSP diagnosis. Several surgical and medical treatments have been described for this disorder, but at this time, optimal management remains uncertain.
Read More
The Society for Maternal-Fetal Medicine consult series #49 on cesarean scar pregnancy
June 11th 2020Cesarean scar pregnancy (CSP) is a complication in which an early pregnancy implants in the scar from a prior cesarean delivery. Incidence and recognition of this condition appear to have increased over the past two decades, perhaps due to high worldwide cesarean delivery rates. The clinical presentation is variable, and many women are asymptomatic at presentation. CSP can be difficult to diagnose in a timely fashion. Ultrasound is the primary imaging modality for CSP diagnosis. Expectantly managed CSP is associated with high rates of severe maternal morbidity such as hemorrhage, placenta accreta spectrum (PAS), and uterine rupture. Given these substantial risks, pregnancy termination is recommended after CSP diagnosis. Several surgical and medical treatments have been described for this disorder, but at this time, optimal management remains uncertain.
Read More
Seven recommendations for mild fetal ventriculomegaly
August 15th 2018Ventriculomegaly, or dilation of the fetal cerebral ventricles, is a relatively common finding on prenatal ultrasound. This summary of SMFM Consult Series #45 reviews key points for diagnosis, evaluation, and management of mild fetal ventriculomegaly.
Read More
Hepatitis C in pregnancy: Screening, treatment, and management
May 10th 2018In the United States, 1% to 2.5% of pregnant women are infected with hepatitis C virus (HCV), which carries an approximately 5% risk of transmission from mother to infant. HCV can be transmitted to an infant in utero or during the peripartum period.
Read More